Genomic Valley Biotech (BOM:539206) ROCE %: 0.16% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:539206 Genomic Valley Biotech Ltd BOM:539206
57 GF Score
Price ₹29.29
GF Value ₹12.92
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Genomic Valley Biotech ROCE %?

Genomic Valley Biotech BOM:539206 +1.00% 57 ROCE % is 0.16% as of Mar. 2026. GuruFocus rates BOM:539206 with a GF Score™ of 57/100 and a GF Value™ of ₹12.92 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genomic Valley Biotech's annualized ROCE % for the quarter that ended in Mar. 2026 was 0.16%.

Genomic Valley Biotech  (BOM:539206) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genomic Valley Biotech ROCE % Related Terms

Genomic Valley Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Genomic Valley Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomic Valley Biotech ROCE % Chart

Genomic Valley Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.80 18.26 0.44 11.86 1.02

Genomic Valley Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 2.53 0.34 1.07 0.16
BOM:539206
57GF Score
Genomic Valley Biotech Ltd BOM:539206
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomic Valley Biotech ROCE % Calculation

Genomic Valley Biotech's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=0.4/( ( (43.566 - 4.579) + (42.496 - 3.208) )/ 2 )
=0.4/( (38.987+39.288)/ 2 )
=0.4/39.1375
=1.02 %

Genomic Valley Biotech's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=0.064/( ( (0 - 0) + (42.496 - 3.208) )/ 1 )
=0.064/( ( 0 + 39.288 )/ 1 )
=0.064/39.288
=0.16 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.16% mean?
Genomic Valley Biotech (BOM:539206) has a ROCE % of 0.16% as of Mar. 2026.
Is Genomic Valley Biotech's ROCE % too high?
Genomic Valley Biotech's current ROCE % is 0.16%. Overall, Genomic Valley Biotech has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomic Valley Biotech's ROCE % compare to VRTX and REGN?
Genomic Valley Biotech's ROCE % of 0.16% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Genomic Valley Biotech's current ROCE % is 0.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomic Valley Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genomic Valley Biotech (BOM:539206) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.92, compared to a current price of ₹29.29 — trading 126.7% above its estimated fair value. The current ROCE % is 0.16%. Genomic Valley Biotech's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Genomic Valley Biotech (BOM:539206), the current ROCE % is 0.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?

Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued. The current stock price of ₹29.29 is trading 126.7% above its estimated GF Value™ of ₹12.92. GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.

Key valuation signals for BOM:539206:

  • ROCE %: 0.16%
  • GF Value™: ₹12.92 vs. price of ₹29.29 (126.7% above fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomic Valley Biotech Business Description

Address 4 K.M. Stone, Berri Charra Road, P.O. Tandaheri, Tehsil-Bahadurgarh, Village Kherka Musalman, Jhajjar, HR, IND, 124507
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
57GF Score

Get the complete analysis for BOM:539206

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹29.29
Price
₹12.92
GF Value